drugset / Trial / NCT02769481

Safety and Efficacy of Bexagliflozin Compared to Glimepiride as Add-on Therapy to Metformin in Type 2 Diabetes Subjects

NCT02769481

Phase 3 Completed 426 enrolled Theracos
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to investigate the effect of bexagliflozin compared to glimepiride as an add-on therapy to metformin in lowering hemoglobin A1c (HbA1c) levels in subjects with type 2 diabetes mellitus (T2DM).

Timeline

Start
2016-08-15
Primary completion
2019-06-14
Completion
2019-06-14

Drugs

EvaluationDrugModalityDoseRoute
Comparator Bexagliflozin Small molecule 20 mg
Comparator Glimepiride Small molecule 2 mg
Comparator Glimepiride Small molecule 4 mg
Comparator Glimepiride Small molecule 6 mg